Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

haemophilus influenzae type b vaccine (Rx)Brand and Other Names:ActHIB, Hiberix, more...Liquid PedvaxHIB

 
 
 

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

injection

  • 10mcg Haemophilus b, 25mcg tetanus toxoid/0.5mL (ActHIB, Hiberix)
  • 7.5mcg Haemophilus b PRP, 125mcg Neisseria meningitidis OMPC/0.5 mL (PedVaxHib)
more...

H. influenzae Type B Immunization

Not indicated for routine immunization in otherwise healthy adults

For more information, see the CDC vaccine guidelines at http://www.cdc.gov/vaccines/schedules/hcp/index.html

Asplenia

  • Indicated for adults with functional or anatomic asplenia (including sickle cell disease) or are undergoing elective splenectomy
  • One dose of HIB vaccine should be administered if HIB vaccine not previously received
  • HIB vaccination should be given ≥14 days before splenectomy

Complement deficiency

  • Indicated for adults with persistent complement component deficiencies
  • One dose of HIB vaccine should be administered if HIB vaccine not previously received

Post-HSCT Recipients

  • Recipients of a hematopoietic stem cell transplant (HSCT) should be vaccinated with a 3-dose regimen 6 to 12 months after a successful transplant, regardless of vaccination history
  • At least 4 weeks should separate doses

Dosing Considerations

Not recommended for adults with HIV infection since their risk for HIB infection is low, unless another risk factor is present (ie, asplenia, complement deficiency, HSCT recipient)

Dosage Forms & Strengths

injection

  • 10mcg Haemophilus b, 25mcg tetanus toxoid/0.5mL (ActHIB, Hiberix)
  • 7.5mcg Haemophilus b PRP, 125mcg Neisseria meningitidis OMPC/0.5 mL (PedVaxHib)
more...

H. influenzae Type B Immunization

IM injection indicated for routine immunization in children aged 2 months to 15 months and up to 5 years for catch up vaccination

Primary series (6 weeks to 12 months): 2 or 3 doses

Booster: 3rd or 4th dose between 12-15 months

PRP-OMP

  • Monovalent vaccine; polyribosylribotol phosphate (PRP) conjugated to outer membrane protein (OMP) complex from Neisseria meningitidis
  • PEDvaxHIB: 2 and 4 months (primary series); 12-15 months (booster)

PRP-T

  • Monovalent vaccines; polyribosylribotol phosphate (PRP) conjugated to tetanus toxoid (T)
  • ActHIB, Hiberix: 0.5 mL IM as 4-dose series at 2, 4, and 6 months (primary series) and between 12-15 months (booster)

Combination vaccines

  • PRP-OMP-HepB (Comvax): 2 and 4 months (primary series); 12-15 months (booster)
  • DTap-IPV/PRP-T (Pentacel): 2, 4, and 6 months (primary series); 12-15 months (booster)
  • MenCY-PRP-T (MenHibRix): 2, 4, and 6 months (primary series); 12-15 months (booster)

Considered fully immunized if

  • At least 1 dose after age 14 months, or
  • 2 doses between 12-14 months old, or
  • >2 doses during first year of life followed by booster when older than 1 yr

Immunosuppressed individuals

  • Consider administering in patients 5 years or older if not already vaccinated and are immunosuppressed (eg, sickle cell disease, leukemia, HIV or anatomic/functional asplenia)

Dosing Considerations

PRP-T: Polyribosylribotol phosphate conjugated to tetanus toxoid

OMP: Outer membrane protein complex from Neisseria meningitidis

Minimum age for vaccination is 6 weeks old for PRP-T (ActHIB), DTaP-IPV/Hib (Pentacel), and Hib-MenCY (MenHibrix), or PRP-OMP (PedvaxHIB, Comvax)

Minimum age for vaccination is 12 months old for PRP-T (Hiberix)

ActHIB: Reconstituted with 0.4% NaCl diluent is indicated for active immunization of children aged 2 months through 5 years for prevention of invasive disease caused by Haemophilus influenzae type b

TriHIBit: ActHIB reconstituted with Tripedia (DTP) vaccine creates TriHIBit vaccine; it is indicated for the active immunization of children aged 15 through 18 months for prevention of invasive disease caused by Haemophilus influenzae type b and diphtheria, tetanus and pertussis

Next

Interactions

Interaction Checker

haemophilus influenzae type b vaccine and

No Results

     
     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            Sort by :  
             activity indicator 
            Previous
            Next

            Adverse Effects

            Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), 1-800-822-7967

            General and by vaccine type

            Irritability (10-70%), drowsiness, fever (0.5-18%), anorexia erythema >2.5cm (0.4-2.2%), swelling, tenderness

            HbOC (HibTITER): erythema (3.3%), fever 2.2%

            PRP-OMP (PedvaxHIB): fever (18.1%), swelling (2.5%), erythema (2.2%)

            PRP-T (ActHIB, OmniHIB): Irritability (72.6%), drowsiness (57.5%), tenderness (46.3%), induration (22.5%), fever (20.1%), anorexia (15.3%), diarrhea (4.4%)

            PRP-D (ProHIBiT): irritability (14%), tenderness (12%), drowsiness (8%), vomiting (7%), fever (2%)

            DTP + HbOC (TETRAMUNE): tenderness, irritability, swelling, erythema, fever

            Frequency Not Defined

            Crying (unusual, high pitched, prolonged)

            Fever

            Irrritability

            Pain

            Sleepiness

            Rash

            Anorexia

            Diarrhea

            Vomiting

            Injection site erythema/induration/pain/soreness/warmth/swelling

            Otitis media

            URI

            Postmarketing Reports

            Anaphylactoid reactions

            Angioedema

            Erythema multiforme

            Facial edema

            Febrile seizure

            Guillain-Barre syndrome

            Headache

            Hypersensitivity

            Hyporesponsive episodes

            Hypotonia

            Injection site abscess

            Lethargy

            Lymphadenopathy

            Malaise

            Mass

            Seizure

            Shock

            Skin discoloration

            Urticaria

            Previous
            Next

            Warnings

            Contraindications

            Severe allergic reaction (eg, anaphylaxis) after a previous dose of any H. influenzae type b- or tetanus toxoid-containing vaccine or any component of the vaccine

            Cautions

            If Guillain-Barré syndrome has occurred within 6 wk of receipt of a prior vaccine containing tetanus toxoid, the decision to give any tetanus toxoid-containing vaccine should be based on careful consideration of the potential benefits and possible risks

            Syncope can occur in association with administration of injectables and may be accompanied by transient neurological signs (eg, visual disturbance, paresthesia, tonic-clonic limb movements): procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope

            Apnea reported following IM vaccination in some infants born prematurely; decisions about when to administer an IM vaccine to infants born prematurely should be based on consideration of the individual infant’s medical status, and the potential benefits and possible risks of vaccination

            Prior to administration, the healthcare provider should review the patient's immunization history for possible vaccine hypersensitivity; epinephrine and other appropriate agents used for the control of immediate allergic reactions must be immediately available should an acute anaphylactic reaction occur

            Safety and effectiveness in immunosuppressed children have not been evaluated; if administered to immunosuppressed children, the expected immune response may not be obtained

            Urine antigen detection may not have a diagnostic value in suspected disease due to H. influenzae type b within 1 to 2 weeks after receipt of a H. influenzae type b-containing vaccine

            Previous
            Next

            Pregnancy & Lactation

            Pregnancy Category: C

            Lactation: Excretion in milk unknown

            Pregnancy Categories

            A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA:Information not available.

            more...
            Previous
            Next

            Pharmacology

            Duration: Unknown

            These products convey active immunity via stimulation of production of endogenously produced antibodies

            The onset of protection from disease is relatively slow, but duration is long lasting (years)

            Mechanism of Action

            Antigenic capsular polysaccharides induce Ab production

            Previous
            Next

            Images

            Previous
            Next

            Formulary

            FormularyPatient Discounts

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Add or Remove Plans
            Plans for
            Select State:
            Non-Medicare PlansMedicare Plans

            Select a box to add or remove a plan.

            Select a class to view formulary status for similar drugs

            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
             
             
             
            All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.